Abbie [Coo_老虎社区_美港股上老虎

2021-12-10

Abbie [Cool]

AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects<blockquote>艾伯维股价上涨；富国银行赞扬增长前景</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":605357672,"tweetId":"605357672","gmtCreate":1639120203620,"gmtModify":1639120203620,"author":{"id":3582629808245810,"idStr":"3582629808245810","authorId":3582629808245810,"authorIdStr":"3582629808245810","name":"VVTZ","avatar":"https://static.tigerbbs.com/2a29e08a133febe21814a6f15264733d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Abbie [Cool]&nbsp;</body></html>","htmlText":"<html><head></head><body>Abbie [Cool]&nbsp;</body></html>","text":"Abbie [Cool]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/605357672","repostId":1101852117,"repostType":4,"repost":{"id":"1101852117","kind":"news","pubTimestamp":1639115859,"share":"https://www.laohunote.com/m/news/1101852117?lang=zh_CN&edition=full","pubTime":"2021-12-10 13:57","market":"us","language":"en","title":"AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects<blockquote>艾伯维股价上涨；富国银行赞扬增长前景</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101852117","media":"TheStreet","summary":"AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of t","content":"AbbVie&nbsp;(ABBV)&nbsp;shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.<blockquote>艾伯维（艾伯维) 富国银行分析师莫希特·班萨尔 (Mohit Bansal) 在跑赢大盘开始报道这家制药巨头的强劲增长前景后，该公司股价周四上涨。</blockquote> He also named it a top pick and has a $165 share-price target.<blockquote>他还将其命名为首选，并设定了 165 美元的目标股价。</blockquote> AbbVie recently traded at $123.54, up 1%. It has climbed 15% year to date, trailing the S&amp;P 500’s 25% gain.<blockquote>艾伯维最近的交易价格为 123.54 美元，上涨 1%。今年迄今为止，该指数已上涨 15%，落后于标普500 25% 的涨幅。</blockquote> While many investors and analysts are focusing on the loss of exclusivity for AbbVie’s rheumatoid arthritis drug, Humira, the “strong growth prospects” of the company’s other treatments are “not yet fully appreciated,” Bansal wrote.<blockquote>班萨尔写道，虽然许多投资者和分析师都在关注艾伯维（AbbVie）类风湿性关节炎药物修美乐（Humira）失去独家经营权一事，但该公司其他治疗药物的 “强劲增长前景 ” “尚未得到充分认识”。</blockquote> “Our head-to-head analysis suggests that ABBV's ex-Humira business is bigger and growing faster than Eli Lilly&nbsp;(LLY)&nbsp;but is trading at 15 times estimated 2022 earnings.” That’s more than a 50% discount to Lilly, he said.<blockquote>“我们的面对面分析表明，ABBV 的前修美乐业务比礼来公司规模更大，增长速度也更快（LLY）但交易价格是 2022 年预期收益的 15 倍。”他说，这比礼来公司打了 50% 以上的折扣。</blockquote> AbbVie has industry-leading 20% compound-annualized growth for earnings per share based on 2021-25 estimates for its non-Humira business, Bansal said.<blockquote>Bansal 表示，根据 2021-25 年非修美乐业务的预测，艾伯维每股收益的年复合增长率为 20%，处于行业领先地位。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects<blockquote>艾伯维股价上涨；富国银行赞扬增长前景</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Shares Rise; Wells Fargo Lauds Growth Prospects<blockquote>艾伯维股价上涨；富国银行赞扬增长前景</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nTheStreet2021-12-10 13:57\n\n</h4>\n</header>\n<article>\nAbbVie&nbsp;(ABBV)&nbsp;shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.<blockquote>艾伯维（艾伯维) 富国银行分析师莫希特·班萨尔 (Mohit Bansal) 在跑赢大盘开始报道这家制药巨头的强劲增长前景后，该公司股价周四上涨。</blockquote> He also named it a top pick and has a $165 share-price target.<blockquote>他还将其命名为首选，并设定了 165 美元的目标股价。</blockquote> AbbVie recently traded at $123.54, up 1%. It has climbed 15% year to date, trailing the S&amp;P 500’s 25% gain.<blockquote>艾伯维最近的交易价格为 123.54 美元，上涨 1%。今年迄今为止，该指数已上涨 15%，落后于标普500 25% 的涨幅。</blockquote> While many investors and analysts are focusing on the loss of exclusivity for AbbVie’s rheumatoid arthritis drug, Humira, the “strong growth prospects” of the company’s other treatments are “not yet fully appreciated,” Bansal wrote.<blockquote>班萨尔写道，虽然许多投资者和分析师都在关注艾伯维（AbbVie）类风湿性关节炎药物修美乐（Humira）失去独家经营权一事，但该公司其他治疗药物的 “强劲增长前景 ” “尚未得到充分认识”。</blockquote> “Our head-to-head analysis suggests that ABBV's ex-Humira business is bigger and growing faster than Eli Lilly&nbsp;(LLY)&nbsp;but is trading at 15 times estimated 2022 earnings.” That’s more than a 50% discount to Lilly, he said.<blockquote>“我们的面对面分析表明，ABBV 的前修美乐业务比礼来公司规模更大，增长速度也更快（LLY）但交易价格是 2022 年预期收益的 15 倍。”他说，这比礼来公司打了 50% 以上的折扣。</blockquote> AbbVie has industry-leading 20% compound-annualized growth for earnings per share based on 2021-25 estimates for its non-Humira business, Bansal said.<blockquote>Bansal 表示，根据 2021-25 年非修美乐业务的预测，艾伯维每股收益的年复合增长率为 20%，处于行业领先地位。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects\">TheStreet</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101852117","content_text":"AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.\nHe also named it a top pick and has a $165 share-price target.\nAbbVie recently traded at $123.54, up 1%. It has climbed 15% year to date, trailing the S&P 500’s 25% gain.\nWhile many investors and analysts are focusing on the loss of exclusivity for AbbVie’s rheumatoid arthritis drug, Humira, the “strong growth prospects” of the company’s other treatments are “not yet fully appreciated,” Bansal wrote.\n“Our head-to-head analysis suggests that ABBV's ex-Humira business is bigger and growing faster than Eli Lilly (LLY) but is trading at 15 times estimated 2022 earnings.” That’s more than a 50% discount to Lilly, he said.\nAbbVie has industry-leading 20% compound-annualized growth for earnings per share based on 2021-25 estimates for its non-Humira business, Bansal said.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":2766,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/605357672"}